APA (7th ed.) Citation

KS, R., JS, L., MM, M., CU, B., I, R., F, T., . . . I, V. (2025). Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors. Cancer research communications, 5(11), 2066. https://doi.org/10.1158/2767-9764.CRC-25-0359

Chicago Style (17th ed.) Citation

KS, Rohrberg, et al. "Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors." Cancer Research Communications 5, no. 11 (2025): 2066. https://doi.org/10.1158/2767-9764.CRC-25-0359.

MLA (9th ed.) Citation

KS, Rohrberg, et al. "Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors." Cancer Research Communications, vol. 5, no. 11, 2025, p. 2066, https://doi.org/10.1158/2767-9764.CRC-25-0359.